Abstract: A hermetically sealed package includes: a heat-dissipating base substrate configured for dissipating heat from the hermetically sealed package; a cap arranged on the heat-dissipating base substrate, the cap and the heat-dissipating base substrate jointly forming at least a part of the package; at least one functional area hermetically sealed by the package; at least one laser bonding line configured for hermetically sealing the package, the laser bonding line having a height perpendicular to a bonding plane of the laser bonding line.

Abstract: A hermetically sealed package includes: at least one cover substrate and a substrate arranged so as to adjoin the at least one cover substrate, which together define at least part of the package, the at least one cover substrate being in a thermally prestressed state and bonded to the substrate adjoining the at least one cover substrate in a hermetically sealing manner by at least one laser bonding line, the at least one cover substrate being made of a material which has a different characteristic value of a coefficient of thermal expansion than the adjoining substrate and a thermal prestress is established in the package; and at least one functional area enclosed in the package.

Abstract: A hermetically sealed package includes: a base substrate and a cover substrate which define at least part of the package, the base substrate and the cover substrate being hermetically sealed to one another by at least one laser bonding line, the at least one laser bonding line having a height perpendicular to its bonding plane, at least the cover substrate including a toughened layer at its surface, at least on a side opposite the at least one laser bonding line; and at least one functional area enclosed in the package.

Abstract: A semiconductor device includes type IV semiconductor base substrate, first and second device areas that are electrically isolated from one another, a first region of type III-V semiconductor material formed over the first device area, a second region of type III-V semiconductor material formed over the second device area, the second region of type III-V semiconductor material being laterally electrically insulated from the first region of type III-V semiconductor material, a first high-electron mobility transistor integrally formed in the first region, and a second high-electron mobility transistor integrally formed in the second region. The first and second high-electron mobility transistors are connected in series. A source terminal of the first high-electron mobility transistor is electrically connected to the first device area. The first device area is electrically isolated from a subjacent intrinsically doped region of the base substrate by a first two-way voltage blocking device.

Abstract: The invention relates to a ball joint (10) for a wiper system, comprising a ball shell (12), a ball head (14) within the ball shell (12), a hinged rod (16) into which the ball shell (12) is inserted, and a securing means (18), wherein the securing means (18) engages around the hinged rod (16), in order to reduce an opening (20) in the ball shell (12) to a blocking distance (d), such that the ball head (15) can be removed from the ball shell (12). The invention further relates to a method for assembling the ball joint (10).

Abstract: The present invention relates to a glass article with low optical loss. The present invention also relates to the use of the glass article, in particular as optical waveguide, for example as light guide plate, in particular in augmented reality devices.

Abstract: A method for preparing and/or carrying out the structuring of a predetermined or predeterminable distinguished surface of a substrate body having a substrate material includes exposing the substrate material in at least one curved effective area to an electromagnetic field which in each of the at least one curved effective area causes a non-linear interaction between the electromagnetic field and the substrate material, and thus at least partially influencing the substrate material arranged in the curved effective area. After the structuring of the distinguished surface the distinguished surface has at least in certain areas at least one first curved progression which is at least partially determined and/or influenced by the curved shape of the at least one curved effective area. The nonlinear interaction causes at least one nonlinear absorption of the electromagnetic field in the substrate material.

Abstract: A semiconductor device includes type IV semiconductor base substrate, first and second device areas that are electrically isolated from one another, a first region of type III-V semiconductor material formed over the first device area, a second region of type III-V semiconductor material formed over the second device area, the second region of type III-V semiconductor material being laterally electrically insulated from the first region of type III-V semiconductor material, a first high-electron mobility transistor integrally formed in the first region, and a second high-electron mobility transistor integrally formed in the second region. The first and second high-electron mobility transistors are connected in series. A source terminal of the first high-electron mobility transistor is electrically connected to the first device area. The first device area is electrically isolated from a subjacent intrinsically doped region of the base substrate by a first two-way voltage blocking device.

Abstract: The present invention relates to bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis and related conditions, and provides a bacterial glutaminyl cyclase (bacQC); an antibody which recognizes the bacQC, a method for identifying an inhibitor of the bacQC; a compound according to Formula (I); a pharmaceutical composition comprising a bacQC inhibitor compound; a bacQC inhibitor compound and/or a pharmaceutical composition for use in a method for treatment of the human or animal body, for use in a method for therapy or prophylaxis of a bacterial infection, and for use in a method for therapy and/or prophylaxis of an acute, chronic or recurrent periodontal disease.

Abstract: A semiconductor device includes type IV semiconductor base substrate, first and second device areas that are electrically isolated from one another, a first region of type III-V semiconductor material formed over the first device area, a second region of type III-V semiconductor material formed over the second device area, the second region of type III-V semiconductor material being laterally electrically insulated from the first region of type III-V semiconductor material, a first high-electron mobility transistor integrally formed in the first region, and a second high-electron mobility transistor integrally formed in the second region. The first and second high-electron mobility transistors are connected in series. A source terminal of the first high-electron mobility transistor is electrically connected to the first device area. The first device area is electrically isolated from a subjacent intrinsically doped region of the base substrate by a first two-way voltage blocking device.

Abstract: The invention relates to humanized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (A? N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of humanized monoclonal antibodies to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of A? N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the humanized antibodies of the invention.

Abstract: A glass container is provided that includes a tube, a circular bottom, and a longitudinal axis. A curved glass heel extends from an outer end the bottom to the first end of the tube. The two-dimensional distance h(x,y) between a contact plane and the outer surface. The two-dimensional distance is measured in a direction parallel to the axis. The slope magnitude of the outer surface at the given position x,y is given by ?{square root over ((dh/dx)2+(dh/dy)2)}. The 75% quantile of values that have been determined for the term ?{square root over ((dh/dx)2+(dh/dy)2)}×d1/h(xy)delta for all given positions x,y within a circular area having a radius of 0.4×d2/2 and that correspond to the centre is less than 4100 ?m/mm. The adjacent positions x,y increase stepwise by 200 ?m, and h(x,y)delta=h(x,y)max?h(x,y)min, h(x,y)max is a maximum value for h(x,y) and h(x,y)min is a minimum value for h(x,y) being determined in that circular area.

Abstract: A glass container is provided that includes a tube, a circular bottom, and a longitudinal axis. A curved glass heel extends from an outer end the bottom to the first end of the tube. The outer surface has a topography defined by a function ?(x) that is an azimuthal average of a distance between a contact plane and the outer surface at any given position located on a circle having the centre and the radius |x|. The values ? for ?(x) are determined for a plurality of circles the radius of which increases stepwise by 500 ?m starting with a circle around the centre having a radius of 500 ?m. The values ? are determined in a range from x=?0.4×d2/2 to x=+0.4×d2/2, d2 having a size such that at least 4 values ? are determined and can be fitted with a curvature function h ^ ? ( x ) = - c × x 2 1 + 1 - c 2 × x 2 + h 0 .

Abstract: The present disclosure relates to a layered optical composite, in particular for use in an augmented reality device. In particular, the disclosure relates to a layered optical composite and a process for its preparation, a device comprising the layered optical composite and a process for its preparation, and the use of a layered optical composite in an augmented reality device. The present disclosure relates to a layered optical composite comprising: a. a substrate having a front face and a back face, b. a coating comprising: i. a type T layer, and ii. a type C region comprising one or more type C layers; in which the substrate has: i. a thickness tG in the range from 0.2 to 1.2 mm; ii. a refractive index nG at a wavelength ? in the range from 1.6 to 2.4; and iii. an optical absorption coefficient KG at the wavelength ? of less than 10 cm?1; in which the type C layers individually and independently have: i. a thickness tC in the range from 9 to 250 nm; ii.

Abstract: A wind turbine blade having a surface mounted device attached thereto via at least a first attachment part, which is connected to a part of the device. The first attachment part comprises an outer attachment part providing a first bonding connection between the device and the surface of the blade, wherein the first bonding connection is an elastic bond, and an inner attachment part providing a second bonding connection between the device and the surface of the blade, wherein the second bonding connection has a structural bond. The structural bond prevents the surface mounted device from creeping and the elastic bond region relieves stresses on the bond line, such as peel stresses, whereby the surface mounted device is less likely to be ripped off the surface of the blade due to forces affecting the device or the blade.

Abstract: The invention relates to humanized and de-immunized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (A? N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of monoclonal antibodies of the invention to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of A? N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the antibodies of the invention.

Abstract: The disclosure relates to a glass window for optical systems, in particular for LiDAR systems, in which the glass window has a curved form. For length scales between 0.1 mm and 15 mm, at least 50% of the area of the glass window has a geometrical slope error SEG for which the following is true: SEG<?2.3·10?6·2·R0[1/mm]+7.3·10?4.

Abstract: A method for preparing a workpiece for separation is provided that includes providing a workpiece that is transparent for light of a pulsed laser beam, splitting the laser beam into two partial beams using an optical system, directing both partial beams onto the workpiece, and moving the workpiece and the partial beams relative to one another. The partial beams are directed onto the workpiece incident at different angles to the normal of the irradiated surface and superimposed inside the workpiece such that the partial beams interfere with one another to form a sequence of intensity maxima inside the workpiece. The intensity at the intensity maxima is sufficiently high to modify the material of the workpiece so that a chain-like periodic pattern of material modifications is formed along a path defining a separation line.

Abstract: The present invention can be included in the field of medicine. Specifically, the present invention provides antibodies and antigen-binding fragments thereof which can bind isoAsp7 amyloid ? (A?) and a pharmaceutical composition comprising the antibodies or antigen-binding fragments thereof. IsoAsp7 A? can be found in plaques of Alzheimer's patients and is thus a suitable target for the treatment and/or prevention of A?-related diseases such as Alzheimer's disease. Thus, the antibodies, antigen-binding fragments thereof and the pharmaceutical composition comprising either can be used to treat and/or prevent neurodegenerative diseases. Further, the present invention provides hybridoma cell lines, the use of the antibodies or antigen-binding fragments thereof for the diagnosis and/or prognosis of a neurodegenerative disease and a method for detecting isoAsp7 A? in an isolated sample.

Abstract: The invention relates to humanized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (A? N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of humanized monoclonal antibodies to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of A? N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the humanized antibodies of the invention.